Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029729 · ClinicalTrials.gov registry record · Phase 1
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
A Phase 1 study of Metastatic or Incurable Non-small Cell Lung Cancer and Relapsed, Refractory Melanoma, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02029729 is a Phase 1 study of Metastatic or Incurable Non-small Cell Lung Cancer and Relapsed, Refractory Melanoma that has completed, run by Biogen. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02029729, a Phase 1 study of Metastatic or Incurable Non-small Cell Lung Cancer and Relapsed, Refractory Melanoma, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this study will help provide clinical information for the design and conduct of further clinical studies with RTA 408 in cancer patients.
Conditions Studied
Interventions
- DRUG omaveloxolone
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center (NSCLC) - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-12-31 |
| Est. Completion | 2015-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02029729
The ClinicalTrials.gov registry entry for NCT02029729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic or Incurable Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which omaveloxolone is the first listed.
NCT02029729 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02029729 about?
NCT02029729 is a clinical study titled "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER". This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this s...
What is the current status of trial NCT02029729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-12-31. Estimated completion is 2015-10-01.
What conditions does trial NCT02029729 study?
This clinical trial studies the following conditions: Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma.
What interventions are being tested in trial NCT02029729?
The interventions under investigation include: omaveloxolone (DRUG).
Who is sponsoring clinical trial NCT02029729?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02029729 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Metastatic or Incurable Non-small Cell Lung Cancer
All registered trials for this condition
Relapsed, Refractory Melanoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.